Alnylam Pharmaceuticals, Inc.
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Abstract:

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.